3rd Nov 2025 07:00
3 November 2025
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Notice of Results
Investor Presentation
Abingdon Health plc (AIM: ABDX) a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, will announce its preliminary results for the year ended 30 June 2025 on Tuesday 11 November 2025.
Investor Presentation
The Company will provide a live presentation relating to the preliminary results via the Investor Meet Company platform on Tuesday 11 November 2025 at 11:00 GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 GMT the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Abingdon Health plc via:
https://www.investormeetcompany.com/abingdon-health-plc/register-investor
Investors who already follow Abingdon Health plc on the Investor Meet Company platform will automatically be invited.
Enquiries:
Abingdon Health plc | www.abingdonhealth.com/investors/ | ||
Chris Hand, Executive Chairman
| Via Walbrook PR | ||
Tom Hayes, Chief Financial Officer
| |||
Zeus (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 3829 5000 | ||
Antonio Bossi / Darshan Patel / Jacob Walker (Corporate Finance) | |||
Nick Searle / Fraser Marshall (Corporate Broking)
|
| ||
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] | ||
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About Abingdon Health plc
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success". Abingdon Analytical Ltd offers performance evaluation for lateral flow and other in vitro diagnostic assays from its Doncaster laboratory.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.
Related Shares:
Abingdon Healt.